<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>IQUIX- levofloxacin solution </strong><br>Vistakon Pharmaceuticals LLC<br></p></div>
<h1>IQUIX<span class="Sup">®</span><br> (levofloxacin ophthalmic solution) 1.5% </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">IQUIX<span class="Sup">®</span> (levofloxacin ophthalmic solution) 1.5% is a sterile topical ophthalmic solution. Levofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of Gram-positive and Gram-negative ocular pathogens. Levofloxacin is a fluorinated 4-quinolone containing a six-member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure.  Levofloxacin is the pure(-)-(<span class="Italics">S</span>)-enantiomer of the racemic drug substance, ofloxacin. It is more soluble in water at neutral pH than ofloxacin.</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=067ea8ec-99a3-4a0b-9116-4ffd6160b24b&amp;name=iquix-01.jpg"></div>
<p>Chemical Name: (-)(<span class="Italics">S</span>)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7<span class="Italics">H</span>-pyrido[1,2,3-de]-1,4 benzoxazine-6-carboxylic acid hemihydrate.</p>
<p>Levofloxacin (hemihydrate) is a yellowish-white crystalline powder. </p>
<p>Each mL of IQUIX<span class="Sup">®</span> contains 15.36 mg of levofloxacin hemihydrate equivalent to 15 mg levofloxacin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>Contains</h2>
<p class="First"><span class="Bold">Active:</span> Levofloxacin 1.5% (15 mg/mL); <span class="Bold">Inactives:</span> glycerin and water. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH to approximately 6.5. IQUIX<span class="Sup">®</span> solution is isotonic with an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 290 mOsm/kg.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Levofloxacin concentration in plasma was measured in 14 healthy adult volunteers during a 16-day course of treatment with IQUIX<span class="Sup">®</span> solution. The dosing schedule was 1-2 drops per eye once in the morning on Days 1 and 16; 1-2 drops per eye every two hours Days 2 through 8; and 1-2 drops per eye every four hours Days 9 through 15. The mean levofloxacin concentration in plasma 1 hour postdose ranged from 3.13 ng/mL on Day 1 to 10.4 ng/mL on Day 16. Maximum mean levofloxacin concentrations increased from 3.22 ng/mL on Day 1 to 10.9 ng/mL on Day 16, which is more than 400 times lower than those reported after standard oral doses of levofloxacin. </p>
<p>Levofloxacin concentration in tears was measured in 100 healthy adult volunteers at various time points following instillation of 2 drops of IQUIX<span class="Sup">®</span> solution. Mean tear concentration measured 15 minutes after instillation was 757 µg/mL.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-2.2"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Levofloxacin is the <span class="Italics">L</span>-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. The antibacterial activity of ofloxacin resides primarily in the <span class="Italics">L</span>-isomer. The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves the inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair, and recombination.</p>
<p>Levofloxacin has <span class="Italics">in vitro</span> activity against a wide range of Gram-negative and Gram-positive microorganisms and is often bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.</p>
<p>Fluoroquinolones, including levofloxacin, differ in chemical structure and mode of action from β-Iactam antibiotics and aminoglycosides, and therefore may be active against bacteria resistant to β-Iactarn antibiotics and aminoglycosides. Additionally, β-Iactam antibiotics and aminoglycosides may be active against bacteria resistant to levofloxacin. Resistance to levofloxacin due to spontaneous mutation <span class="Italics">in vitro</span> is a rare occurrence (range: 10<span class="Sup">-9</span> to 10<span class="Sup">-10</span>).</p>
<p>Levofloxacin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND USAGE section:</p>
<table width="100%">
<col align="left" valign="baseline" width="50%">
<col align="left" valign="baseline" width="50%">
<thead><tr class="Botrule First Last Toprule">
<th align="left">AEROBIC GRAM-POSITIVE MICROORGANISMS:</th>
<th align="left">AEROBIC GRAM-NEGATIVE MICROORGANISMS:</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td align="left">
<span class="Italics">Corynebacterium</span> species 												<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td align="left"><span class="Italics">Pseudomonas aeruginosa</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td align="left">
<span class="Italics">Serratia marcescens</span><a href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left"><span class="Italics">Staphylococcus epidermidis</span></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Italics">Streptococcus pneumoniae</span></td>
<td align="left"></td>
</tr>
<tr class="Botrule Last">
<td align="left">
<span class="Italics">Viridans</span> group streptococci <a href="#footnote-1" class="Sup">*</a>
</td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p>The following <span class="Italics">in vitro</span> data are also available, <span class="Underline">but their clinical significance in ophthalmic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is unknown. The safety and effectiveness of levofloxacin in treating ophthalmological <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled trials.</span></p>
<p>These organisms are considered susceptible when evaluated using systemic breakpoints. However, a correlation between the <span class="Italics">in vitro</span> systemic breakpoint and ophthalmological efficacy has not been established. The list of organisms is provided as guidance only in assessing the potential treatment of <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcer</span>. Levofloxacin exhibits <span class="Italics">in vitro</span> minimal inhibitory concentrations (MICs) of 2 µg/mL or less (systemic susceptible breakpoint) against most (≥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following ocular pathogens:</p>
<table width="100%">
<col align="left" valign="baseline" width="100%">
<thead><tr class="Botrule First Last Toprule"><th align="left">AEROBIC GRAM-POSITIVE MICROORGANISMS:</th></tr></thead>
<tbody>
<tr class="Botrule First Toprule"><td align="left">
<span class="Italics">Enterococcus faecalis </span>(many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are only moderately susceptible)</td></tr>
<tr><td align="left"><span class="Italics">Staphylococcus saprophyticus</span></td></tr>
<tr><td align="left"><span class="Italics">Streptococcus agalactiae</span></td></tr>
<tr><td align="left"><span class="Italics">Streptococcus pyogenes</span></td></tr>
<tr><td align="left">
<span class="Italics">Streptococcus</span> (Group C/F)</td></tr>
<tr class="Botrule Last"><td align="left">
<span class="Italics">Streptococcus</span> (Group G)</td></tr>
</tbody>
</table>
<table width="100%">
<col align="left" valign="baseline" width="50%">
<col align="left" valign="baseline" width="50%">
<thead><tr class="Botrule First Last Toprule"><th align="left" colspan="2">AEROBIC GRAM-NEGATIVE MICROORGANISMS:</th></tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left"><span class="Italics">Acinetobacter baumannii</span></td>
<td align="left"><span class="Italics">Legionella pneumophila</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Acinetobacter Iwoffii</span></td>
<td align="left"><span class="Italics">Moraxella catarrhalis</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Citrobacter koseri</span></td>
<td align="left"><span class="Italics">Morganella morganii</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Citrobacter freundii</span></td>
<td align="left"><span class="Italics">Neisseria gonorrhoeae</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Enterobacter aerogenes</span></td>
<td align="left"><span class="Italics">Pantoea agglomerans</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Enterobacter cloacae</span></td>
<td align="left"><span class="Italics">Proteus mirabilis</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Escherichia coli</span></td>
<td align="left"><span class="Italics">Proteus vulgaris</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Haemophilus influenzae</span></td>
<td align="left"><span class="Italics">Providencia rettgeri</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Haemophilus parainfluenzae</span></td>
<td align="left"><span class="Italics">Providencia stuartii</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Klebsiella oxytoca</span></td>
<td align="left"><span class="Italics">Pseudomonas fluorescens</span></td>
</tr>
<tr class="Botrule Last">
<td align="left"><span class="Italics">Klebsiella pneumoniae</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-2.3"></a><p></p>
<h2>Clinical Studies</h2>
<p class="First">In two randomized, double-masked, multicenter controlled clinical trials of 280 patients with positive cultures, subjects were dosed with IQUIX<span class="Sup">®</span> or ofloxacin 0.3% ophthalmic solution. Dosing occurred on Days 1 through 3 every two hours while awake and 4 and 6 hours after retiring. Dosing occurred on Day 4 through treatment completion 4 times daily while awake. Clinical cure was defined as complete re-epithelialization and no progression of the infiltrate for two consecutive visits. The IQUIX<span class="Sup">®</span> treated subjects had an approximately equal mean clinical cure rate of 80% (73% to 87%) compared to 84% (82% to 86%) for the subjects treated with ofloxacin 0.3% ophthalmic solution.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">IQUIX<span class="Sup">®</span> solution is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcer</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following bacteria:</p>
<table width="100%">
<col align="left" valign="baseline" width="50%">
<col align="left" valign="baseline" width="50%">
<thead><tr class="Botrule First Last Toprule">
<th align="left">GRAM-POSITIVE BACTERIA:</th>
<th align="left">GRAM-NEGATIVE BACTERIA:</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td align="left">
<span class="Italics">Corynebacterium</span> species 										<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td align="left"><span class="Italics">Pseudomonas aeruginosa</span></td>
</tr>
<tr>
<td align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td align="left">
<span class="Italics">Serratia marcescens</span><a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left"><span class="Italics">Staphylococcus epidermidis</span></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Italics">Streptococcus pneumoniae</span></td>
<td align="left"></td>
</tr>
<tr class="Botrule Last">
<td align="left">
<span class="Italics">Viridans</span> group streptococci<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="left"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">IQUIX<span class="Sup">®</span> solution is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to levofloxacin, to other quinolones, or to any of the components in this medication.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">NOT FOR INJECTION.</p>
<p>IQUIX<span class="Sup">®</span> solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.</p>
<p>In patients receiving systemic quinolones, serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including laryngeal, pharyngeal or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>), airway obstruction, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to levofloxacin occurs, discontinue the drug. Serious acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, induding fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.</p>
<p>Patients should be advised not to wear contact lenses if they have signs and symptoms of <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcer</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Avoid contaminating the applicator tip with material from the eye, fingers or other source.</p>
<p>Systemic quinolones have been associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, even following a single dose. Discontinue use immediately and contact your physician at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Specific drug interaction studies have not been conducted with IQUIX<span class="Sup">®</span>. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a long term carcinogenicity study in rats, levofloxacin exhibited no carcinogenic or tumorigenic potential following daily dietary administration for 2 years; the highest dose (100 mg/kg/day) was 100 times the highest recommended human ophthalmic dose.</p>
<p>Levofloxacin was not mutagenic in the following assays: Ames bacterial mutation assay <span class="Italics">(S. typhimurium</span> and <span class="Italics">E. coli)</span>, CHO/HGPRT forward mutation assay, mouse micronucleus test, mouse dominant lethal test, rat unscheduled DNA synthesis assay, and the <span class="Italics">in vivo</span> mouse sister chromatid exchange assay. It was positive in the <span class="Italics">in vitro</span> chromosomal aberration (CHL cell line) and <span class="Italics">in vitro</span> sister chromatid exchange (CHL/IU cell line) assays.</p>
<p>Levofloxacin caused no impairment of fertility or reproduction in rats at oral doses as high as 360 mg/kg/day, corresponding to 400 times the highest recommended human ophthalmic dose.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Levofloxacin at oral doses of 810 mg/kg/day in rats, which corresponds to approximately 1000 times the highest recommended human ophthalmic dose, caused decreased fetal body weight and increased fetal mortality.</p>
<p>No teratogenic effect was observed when rabbits were dosed orally as high as 50 mg/kg/day, which corresponds to approximately 60 times the highest recommended maximum human ophthalmic dose, or when dosed intravenously as high as 25 mg/kg/day, corresponding to approximately 30 times the highest recommended human ophthalmic dose.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Levofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Levofloxacin has not been measured in human milk. Based upon data from ofloxacin, it can be presumed that levofloxacin is excreted in human milk. Caution should be exercised when IQUIX<span class="Sup">®</span> is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children below the age of six years have not been established. Oral administration of systemic quinolones has been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals. There is no evidence that the ophthalmic administration of levofloxacin has any effect on weight bearing joints.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and other adult patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequently reported adverse events in the overall study population were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and a <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span> following instillation. These events occurred in approximately 8–10% of patients.</p>
<p>Adverse events occurring in approximately 1–2% of patients included decreased/<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, instillation site irritation/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, and <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>.</p>
<p>Other reported ocular reactions occurring in less than 1% of patients included <span class="product-label-link" type="condition" conceptid="380117" conceptname="Conjunctival edema">chemosis</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcer</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4034681" conceptname="Vitreous floaters">floaters</span>, <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">hyperemia</span>, lid <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and lid <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Days 1 through 3</h2>
<p class="First">Instill one to two drops in the affected eye(s) every 30 minutes to 2 hours while awake and approximately 4 and 6 hours after retiring.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Day 4 through treatment completion</h2>
<p class="First">Instill one to two drops in the affected eye(s) every 1 to 4 hours while awake.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">IQUIX<span class="Sup">®</span> (levofloxacin ophthalmic solution) 1.5% is supplied in a white, low density polyethylene bottle with a controlled dropper tip and a tan, high density polyethylene cap in the following size:</p>
<p> 5 mL fill in 5 cc container– NDC 68669-145-05</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-9.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at 15° – 25°C (59°– 77°F).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First">Rx Only.</p>
<p><span class="Bold">Manufactured by:</span><br>Santen Oy, P.O. Box 33, FIN-33721 Tampere, Finland</p>
<p><span class="Bold">Marketed by:</span><br> VISTAKON<span class="Sup">®</span> Pharmaceuticals, LLC <br>Jacksonville, FL 32256 USA</p>
<p>Licensed from: <br>Daiichi Sankyo Co., Ltd., Tokyo, Japan</p>
<p>U.S. PAT. NO 5,053,407</p>
<p>April 2007 Version</p>
<p>3221050/3</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-10"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5mL Carton</h1>
<p class="First">NDC 68669-145-05</p>
<p><span class="Bold">IQUIX<span class="Sup">®</span></span><br>(levofloxacin ophthalmic <br>solution) 1.5%</p>
<p>Sterile</p>
<p><span class="Bold">5mL</span></p>
<p><span class="Bold">VISTAKON<span class="Sup">®</span><br>PHARMACEUTICALS, LLC</span></p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=067ea8ec-99a3-4a0b-9116-4ffd6160b24b&amp;name=iquix-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IQUIX 		
					</strong><br><span class="contentTableReg">levofloxacin solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68669-145</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>levofloxacin</strong> (levofloxacin) </td>
<td class="formItem">levofloxacin</td>
<td class="formItem">15 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycerin</strong></td>
<td class="formItem">22 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68669-145-99</td>
<td class="formItem">1 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:68669-145-05</td>
<td class="formItem">5 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021571</td>
<td class="formItem">06/01/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Vistakon Pharmaceuticals LLC
							(004060273)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6236a560-8bb3-4002-9208-979b8f06eaac</div>
<div>Set id: 067ea8ec-99a3-4a0b-9116-4ffd6160b24b</div>
<div>Version: 3</div>
<div>Effective Time: 20100318</div>
</div>
</div> <div class="DistributorName">Vistakon Pharmaceuticals LLC</div></p>
</body></html>
